SCTX (Scribe Therapeutics) EBITDA Margin %: -705.24% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics EBITDA Margin %?

Scribe Therapeutics SCTX -13.40% 8 EBITDA Margin % is -705.24% as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Scribe Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-15.75 Mil. Scribe Therapeutics's Revenue for the three months ended in Mar. 2026 was $2.23 Mil. Therefore, Scribe Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -705.24%.

Scribe Therapeutics  (NAS:SCTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Scribe Therapeutics EBITDA Margin % Related Terms

Scribe Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics EBITDA Margin % Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
EBITDA Margin %
-117.79 -35.45

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
EBITDA Margin % 0.00 -13.31 0.00 -705.24

SCTX vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Scribe Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's EBITDA Margin % falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Scribe Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-18.14/51.174
=-35.45 %

Scribe Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.748/2.233
=-705.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -705.24% mean?
Scribe Therapeutics (SCTX) has a EBITDA Margin % of -705.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' EBITDA Margin % too high?
Scribe Therapeutics' current EBITDA Margin % is -705.24%. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' EBITDA Margin % compare to ?
Scribe Therapeutics' EBITDA Margin % of -705.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current EBITDA Margin % is -705.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current EBITDA Margin % of -705.24%. The current EBITDA Margin % is -705.24%. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current EBITDA Margin % is -705.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price